Not exact matches
Scientists have uncovered
how tumor cells in
aggressive uterine cancer can switch disguises and spread so quickly to other parts of the body.
Many biomarkers are available for estimating
tumor mass, but a possibly more important aspect of a
tumor's pathology is
how aggressive it is and
how fast it is growing.
«By understanding
how stress accelerates invasion in
aggressive breast
tumor cells, this work will inform future studies into whether beta - blockers could be a useful adjuvant therapy in the treatment of some
aggressive breast cancers.»
Little is known about
how CNS - PNETs develop, although these
tumors are more
aggressive than other PNETs and have an overall survival rate of only about 20 percent.
Answering important clinical questions — such as whether genetic diversity is a risk factor for
aggressive tumor development or
how it relates to treatment resistance — requires analyzing samples from many patients with different types of cancer.
It has been recognized that the more
aggressive triple - negative breast cancer occurs more frequently in African American women, but no previous study has examined racial differences in
tumor genotype and
how they might contribute to the risk of cancer recurrence.
«Low oxygen, high risk:
How tumors adapt to become more
aggressive.»
As this variant also appears to be associated with the development of more
aggressive prostate
tumors, a diagnostic test for the variant may enable doctors to make more informed decisions as to
how closely they should monitor those who are at high risk, and
how aggressively they should treat the disease once it presents.
Researchers led by St. Jude Children's Research Hospital scientists have worked out
how a crucial cancer - related protein, a «histone writer» called Ezh2, plays a role in suppressing as well as driving the most
aggressive form of the brain
tumor medulloblastoma.
Systemic symptoms depend on the location and type of
tumor,
how aggressive it is and whether it has metastasized.
The cells are sent to a laboratory, which can determine whether the
tumor is benign or malignant with enough accuracy to determine
how aggressive the surgical approach should be.